Feedback
Settings

Settings

Goto Application

8,599 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 860
1.20250222101Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine
US - 10.07.2025
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No 19018613 Applicant Mammal Labs LLC Inventor Thomas A. Schultz

A composition for treatment of African Swine Fever in swine includes avian-sourced antibodies specific for an African Swine Fever Virus isolate. These antibodies are produced by avian animals immunized against the African Swine Fever Virus isolate and mixed with a protective/reactive matrix obtained from, isolated from, or derived from, non-hyperimmune colostrum.

2.4582444C-TYPE SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS, AND USE
EP - 09.07.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 23852032 Applicant WUHAN BANKE BIOTECHNOLOGY CO LTD Inventor GONG RUI
The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. Compared with an full-length monoclonal antibody, the C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.
3.4580677SARS-COV2 ANTIBODIES AND USES THEREOF
EP - 09.07.2025
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No 23861489 Applicant INVIVYD INC Inventor WALKER LAURA

The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

4.4581050COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ORTHOPOXVIRUS INFECTIONS
EP - 09.07.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No 23861274 Applicant BIOFACTURA INC Inventor SAMPEY DARRYL BACON

Provided herein are antibodies and functional fragments thereof for treating or preventing viral diseases, for example pox viral diseases, for example smallpox and monkey pox. Any antibody or functional fragment thereof described herein can be an engineered antibody or engineered antibody fragment. Also, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Further provided herein are kits containing one or more antibodies or functional fragments thereof, and methods, dosing schedules, dosage amounts, and routes of administration of antibodie(s) and functional fragment(s) thereof. Finally are provided methods of making antibodies and functional fragments thereof.

5.4580678TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
EP - 09.07.2025
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
 Appl.No 23859503 Applicant UNITED BIOPHARMA INC Inventor KUO BE-SHENG

The present invention relates to the treatment of herpes simplex virus (HSV) infection using an anti-HSV antibody. In particular, the anti-HSV antibody specifically binds to the glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). The treatment of the present invention is effective against drug-resistant and/or recurrent HSV infection.

6.WO/2025/140539ULTRAPOTENT BROARDLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF
WO - 03.07.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/CN2024/143146 Applicant THE UNIVERSITY OF HONG KONG Inventor CHEN, Zhiwei
Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.
7.822545ANTIBODIES AGAINST METAPNEUMOVIRUS FUSION (F) PROTEIN AND USES THEREOF
NZ - 27.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 822545 Applicant ICOSAVAX, INC. Inventor FELDHAUS, Andrew, L.
Provided are epitope-specific antigen-binding molecules specific to a human metapneumovirus (hMPV) Fusion (F) protein, in which the antigen-binding molecule comprises a variable domain that contacts the hMPV F protein. The antigen-binding molecule specific to an hMPV F protein comprises a heavy chain and a light chain. Further provided are methods for detecting antibodies specific to an hMPV F protein, a method comprising: a.) contacting a biological sample with an hMPV F protein; and b.) contacting an epitope-specific antigen-binding molecule with the hMPV F protein.
8.821351STABILIZED VACCINES
NZ - 27.06.2025
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No 821351 Applicant SEQIRUS INC. Inventor WEN, Yingxia
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
9.WO/2025/137632ANTIBODIES AGAINST HENIPAVIRUSES
WO - 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2024/061561 Applicant MAPP BIOPHARMACEUTICAL, INC. Inventor WEST, Brandyn
Provided herein are Henipavirus antibodies. These Henipavirus antibodies bind to the Henipavirus F glycoprotein and have neutralizing activity against different Henipavirus species and strains. These antibodies are used in methods of inducing an immune response and methods of inhibiting Henipavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.
10.120192406一种抑制本迪布焦型和扎依尔型埃博拉病毒感染的纳米抗体
CN - 24.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 202510326241.3 Applicant 中国医学科学院病原生物学研究所 Inventor 杨威
本发明公开了一种抑制本迪布焦型和扎依尔型埃博拉病毒感染的纳米抗体。本发明属于生物技术领域，具体涉及一种抑制本迪布焦型和扎依尔型埃博拉病毒感染的纳米抗体。本发明靶向埃博拉病毒的纳米抗体BDBV‑Nb02具有3个互补决定簇CDR1、CDR2和CDR3；CDR1的氨基酸序列为SEQ ID No:1的第27‑33位，CDR2的氨基酸序列为SEQ ID No:1的第47‑58位，CDR3的氨基酸序列为SEQ ID No:1的第97‑109位。纳米抗体BDBV‑Nb02对本迪布焦型埃博拉病毒和扎伊尔型埃博拉病毒呈现中和作用，在医学领域具有重要的应用前景和创新意义。
# -